Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K current report with the SEC on September 28, 2026 reporting Item 8.01 (Other Events). 4SIGHT Phase 3 DME trial initiated across multiple sites, enrolling 514 treatment-naïve patients globally.
4D Molecular Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- 4SIGHT Phase 3 DME trial initiated across multiple sites, enrolling 514 treatment-naïve patients globally
- Single 4SIGHT trial could support U.S. and European filings, leveraging FDA Regenerative Medicine Advanced Therapy designation
- SPECTRA Phase 3-dose cohort showed +10.8 BCVA letters and -176 µm CST reduction at 2 years
- 61% treatment-burden reduction versus projected aflibercept Q8W, with 2 of 9 patients injection-free
- Safety profile in 22 patients included no intraocular inflammation or ocular serious adverse events over 2 years
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other 4D Molecular Therapeutics, Inc. 8-K filings
Get the next FDMT 8-K as it lands
Follow FDMT for push alerts, or ask the research agent what this filing means.